Trending News

Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire

TOOLS

Technical Analysis Screener

Top Analyst Stocks

Popular

Top Smart Score Stocks

Popular

AI Analyst Top Stocks

Daily Analyst Ratings

Daily Insiders Trades

Dividend Stocks

ETF Center

Top Gainers/losers/active ETFs

Trump Dashboard

New

Dividend Calculator

Options Profit Calculator

Dollar Cost Averaging

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Education

About Us

Working with TipRanks

STOCKS

Blueprint Medicines Corp. (BPMC)

:BPMC

BPMC

Blueprint Medicines

Overview

RESEARCH TOOLS

Top Analyst Stocks

Top Smart Score Stocks

Stock Screener

reports

Blueprint Medicines (BPMC) Price & Analysis

Compare

― Followers

BPMC Stock Chart & Stats

Day’s RangeN/A

52-Week Range― - ―

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

BetaN/A

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Blueprint Medicines News

Cogent Biosciences price target raised to $22 from $15 at Citi

Citi raised the firm’s price target on Cogent Biosciences (COGT) to $22 from $15 and keeps a Buy...

2M ago

BPMC

COGT

Blueprint Medicines Completes $9.1B Merger, Delists from Nasdaq

An update from Blueprint Medicines ( ($BPMC) ) is now available. On July 17, 2025, Blueprint Medicines completed...

2M ago

BPMC

Blueprint Medicines Holds Annual Stockholders Meeting

Blueprint Medicines ( ($BPMC) ) has provided an announcement. On June 18, 2025, Blueprint Medicines held its Annual...

3M ago

BPMC

Blueprint Medicines downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $129, down...

3M ago

BPMC

Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT

Blueprint Medicines (BPMC) “announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates...

3M ago

BPMC

Blueprint Medicines price target raised to $129 from $88 at UBS

UBS analyst David Lai raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $88 and...

3M ago

BPMC

Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $102 and keeps an...

3M ago

SNY

BPMC

Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Blueprint Medicines (BPMC...

3M ago

BPMC

Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

Blueprint Medicines upgraded to Neutral from Sell at Citi

Citi upgraded Blueprint Medicines (BPMC) to Neutral from Sell with a price target of $129, up from $83,...

3M ago

BPMC

Blueprint Medicines downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Michael Schmidt downgraded Blueprint Medicines (BPMC) to Neutral from Buy with a $132 price target after...

3M ago

BPMC

Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

AAP

CAH

Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens

Stephens downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $135, down from...

3M ago

BPMC

Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Blueprint Medicines (BPMC...

3M ago

BPMC

BPMC FAQ

What was Blueprint Medicines Corp.’s price range in the past 12 months?

Currently, no data Available

What is Blueprint Medicines Corp.’s market cap?

Currently, no data Available

When is Blueprint Medicines Corp.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Blueprint Medicines Corp.’s earnings last quarter?

Currently, no data Available

Is Blueprint Medicines Corp. overvalued?

According to Wall Street analysts Blueprint Medicines Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Blueprint Medicines Corp. pay dividends?

Blueprint Medicines Corp. does not currently pay dividends.

What is Blueprint Medicines Corp.’s EPS estimate?

Blueprint Medicines Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Blueprint Medicines Corp. have?

Currently, no data Available

What happened to Blueprint Medicines Corp.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Blueprint Medicines Corp.?

Currently, no hedge funds are holding shares in BPMC

Company Description

Blueprint Medicines Corp.

Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on developing targeted treatments for genomically defined cancers, rare diseases, and cancer immunotherapy. The company leverages its proprietary scientific platform to create small molecule medicines that selectively target genetic drivers of disease. Blueprint Medicines aims to improve patient outcomes through the development of transformative therapies that address the underlying causes of various diseases.